User profiles for M. A. Mall

Marcus A. Mall

Charité - Universitätsmedizin Berlin
Verified email at charite.de
Cited by 24416

The future of cystic fibrosis care: a global perspective

SC Bell, MA Mall, H Gutierrez, M Macek… - The Lancet …, 2020 - thelancet.com
The past six decades have seen remarkable improvements in health outcomes for people
with cystic fibrosis, which was once a fatal disease of infants and young children. However, …

Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models

MA Mall - Journal of aerosol medicine and pulmonary drug …, 2008 - liebertpub.com
… (61) In contrast to CF patients, in whom chronic obstructive lung disease remains the ma- …
Goodman RM, Yergin BM, Landa JF, Golivanux MH, and Sackner MA: Relationship of smoking …

The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease

…, SY Graeber, A Dalpke, C Schultz, MA Mall - Journal of Cystic …, 2011 - Elsevier
… [24] Mall MA. Role of the amiloride-sensitive epithelial Na+ channel in the pathogenesis
and as a therapeutic target for cystic fibrosis lung disease. Exp Physiol 2009;94:171–4. …

[HTML][HTML] SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

…, E Baysal, M Mangold, L Henze, R Lauster, MA Mall… - Nature, 2020 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly
unfolding coronavirus disease 2019 (COVID-19) pandemic 1, 2. Clinical manifestations of …

[HTML][HTML] Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele

PG Middleton, MA Mall, P Dřevínek… - … England Journal of …, 2019 - Mass Medical Soc
Background Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis
transmembrane conductance regulator (CFTR) protein, and nearly 90% of patients have at …

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double …

…, E Van Braeckel, SM Rowe, E Tullis, MA Mall… - The Lancet, 2019 - thelancet.com
… At week 4, treatment with elexacaftor plus tezacaftor plus ivacaftor resulted in a least squares
mean increase in body-mass index (BMI) of 0·60 kg/m 2 (95% CI 0·41 to 0·79; nominal p<0·…

Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination

…, MA Müller, B Sawitzki, S Miltenyi, F Paul, MA Mall… - Science, 2021 - science.org
INTRODUCTION The clinical manifestations of COVID-19 vary from asymptomatic infection
to respiratory failure. Severe disease courses are primarily associated with advanced age, …

[HTML][HTML] VX-445–tezacaftor–ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles

…, G Marigowda, L Burr, C Daines, MA Mall… - New england journal …, 2018 - Mass Medical Soc
Background VX-445 is a next-generation cystic fibrosis transmembrane conductance regulator
(CFTR) corrector designed to restore Phe508del CFTR protein function in patients with …

[HTML][HTML] Triple Therapy for Cystic Fibrosis Phe508del–Gating and –Residual Function Genotypes

PJ Barry, MA Mall, A Álvarez, C Colombo… - … England Journal of …, 2021 - Mass Medical Soc
Background Elexacaftor–tezacaftor–ivacaftor is a small-molecule cystic fibrosis transmembrane
conductance regulator (CFTR) modulator regimen shown to be efficacious in patients …

[HTML][HTML] SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself

…, G Schönrich, M Raftery, T Kallinich, MA Mall… - Nature …, 2021 - nature.com
The pathogenesis of severe COVID-19 reflects an inefficient immune reaction to SARS-CoV-2.
Here we analyze, at the single cell level, plasmablasts egressed into the blood to study …